Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial | Osteoporosis | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Macdonald  HM, Reid  IR, Gamble  GD, Fraser  WD, Tang  JC, Wood  AD.  25-Hydroxyvitamin D threshold for the effects of vitamin D supplements on bone densityl.  J Bone Miner Res. 2018;33(8):1464-1469. doi:10.1002/jbmr.3442PubMedGoogle ScholarCrossref
2.
Reid  IR, Horne  AM, Mihov  B,  et al.  Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial.  J Intern Med. 2017;282(5):452-460. doi:10.1111/joim.12651PubMedGoogle ScholarCrossref
3.
Reid  IR, Bolland  MJ, Grey  A.  Effects of vitamin D supplements on bone mineral density.  Lancet. 2014;383(9912):146-155. doi:10.1016/S0140-6736(13)61647-5PubMedGoogle ScholarCrossref
4.
Bolland  MJ, Grey  A, Avenell  A.  Effects of vitamin D supplementation on musculoskeletal health.  Lancet Diabetes Endocrinol. 2018;6(11):847-858. doi:10.1016/S2213-8587(18)30265-1PubMedGoogle ScholarCrossref
5.
Avenell  A, Mak  JCS, O’Connell  D.  Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.  Cochrane Database Syst Rev. 2014;39(4):CD000227. doi:10.1002/14651858.CD000227.pub4.PubMedGoogle Scholar
6.
Institute of Medicine.  Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
7.
Hanley  DA, Cranney  A, Jones  G,  et al; Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada.  Vitamin D in adult health and disease.  CMAJ. 2010;182(12):E610-E618. doi:10.1503/cmaj.080663PubMedGoogle ScholarCrossref
8.
Vieth  R, Chan  PC, MacFarlane  GD.  Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level.  Am J Clin Nutr. 2001;73(2):288-294. doi:10.1093/ajcn/73.2.288PubMedGoogle ScholarCrossref
9.
Rooney  MR, Harnack  L, Michos  ED, Ogilvie  RP, Sempos  CT, Lutsey  PL.  Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 international units daily, 1999-2014.  JAMA. 2017;317(23):2448-2450. doi:10.1001/jama.2017.4392PubMedGoogle ScholarCrossref
10.
Grimnes  G, Joakimsen  R, Figenschau  Y, Torjesen  PA, Almås  B, Jorde  R.  The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial.  Osteoporos Int. 2012;23(1):201-211. doi:10.1007/s00198-011-1752-5PubMedGoogle ScholarCrossref
11.
Samelson  EJ, Broe  KE, Xu  H,  et al.  Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC).  Lancet Diabetes Endocrinol. 2019;7(1):34-43. doi:10.1016/S2213-8587(18)30308-5PubMedGoogle ScholarCrossref
12.
Burt  LA, Gaudet  S, Kan  M,  et al.  Methods and procedures for: a randomized double-blind study investigating dose-dependent longitudinal effects of vitamin D supplementation on bone health.  Contemp Clin Trials. 2018;67:68-73. doi:10.1016/j.cct.2018.02.009PubMedGoogle ScholarCrossref
13.
Bouillon  R.  Genetic and racial differences in the vitamin D endocrine system.  Endocrinol Metab Clin North Am. 2017;46(4):1119-1135. doi:10.1016/j.ecl.2017.07.014PubMedGoogle ScholarCrossref
14.
Wu  H, Gozdzik  A, Barta  JL,  et al.  The development and evaluation of a food frequency questionnaire used in assessing vitamin D intake in a sample of healthy young Canadian adults of diverse ancestry.  Nutr Res. 2009;29(4):255-261. doi:10.1016/j.nutres.2009.03.006PubMedGoogle ScholarCrossref
15.
Papaioannou  A, Morin  S, Cheung  AM,  et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.  CMAJ. 2010;182(17):1864-1873. doi:10.1503/cmaj.100771PubMedGoogle ScholarCrossref
16.
Ellouz  R, Chapurlat  R, van Rietbergen  B, Christen  P, Pialat  JB, Boutroy  S.  Challenges in longitudinal measurements with HR-pQCT.  Bone. 2014;63:147-157. doi:10.1016/j.bone.2014.03.001PubMedGoogle ScholarCrossref
17.
Manske  SL, Davison  EM, Burt  LA, Raymond  DA, Boyd  SK.  The estimation of second-generation HR-pQCT from first-generation HR-pQCT using in vivo cross-calibration.  J Bone Miner Res. 2017;32(7):1514-1524. doi:10.1002/jbmr.3128PubMedGoogle ScholarCrossref
18.
Biodex Medical Systems Inc.  Biosway portable balance system. 2017. http://www.biodex.com/physical-medicine/products/balance/biosway-portable. August 30, 2018.
19.
Roberts  HC, Denison  HJ, Martin  HJ,  et al.  A review of the measurement of grip strength in clinical and epidemiological studies.  Age Ageing. 2011;40(4):423-429. doi:10.1093/ageing/afr051PubMedGoogle ScholarCrossref
20.
Podsiadlo  D, Richardson  S.  The timed “Up & Go”.  J Am Geriatr Soc. 1991;39(2):142-148. doi:10.1111/j.1532-5415.1991.tb01616.xPubMedGoogle ScholarCrossref
21.
Ware  JE, Kosinski  M, Dewey  JE.  How to Score Version 2 of the SF-36 Health Survey. Lincoln, Rhode Island: QualityMetric; 2000.
22.
Burt  L, Ménard  AL, Macdonald  HM, Hanley  DA, Boyd  SK.  A five-year longitudinal study of site-specific changes in bone quality in the Calgary population-based cohort: an HR-pQCT study [2013 ASBMR Annual Meeting oral presentation 1082].  J Bone Miner Res. 2013;28(suppl 1).Google Scholar
23.
 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction.  Lancet. 1988;2(8607):349-360.PubMedGoogle Scholar
24.
Coffman  CJ, Edelman  D, Woolson  RF.  To condition or not condition? analysing ‘change’ in longitudinal randomised controlled trials.  BMJ Open. 2016;6(12):e013096. doi:10.1136/bmjopen-2016-013096PubMedGoogle Scholar
25.
Molenberghs  G, Thijs  H, Jansen  I,  et al.  Analyzing incomplete longitudinal clinical trial data.  Biostatistics. 2004;5(3):445-464. doi:10.1093/biostatistics/kxh001PubMedGoogle ScholarCrossref
26.
Wellek  S, Ziegler  A.  Cochran-Armitage test versus logistic regression in the analysis of genetic association studies.  Hum Hered. 2012;73(1):14-17. doi:10.1159/000334085PubMedGoogle ScholarCrossref
27.
Aloia  J, Dhaliwal  R, Mikhail  M,  et al.  Free 25(OH)D and calcium absorption, PTH, and markers of bone turnover.  J Clin Endocrinol Metab. 2015;100(11):4140-4145. doi:10.1210/jc.2015-2548PubMedGoogle ScholarCrossref
28.
Takeda  S, Yoshizawa  T, Nagai  Y,  et al.  Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells.  Endocrinology. 1999;140(2):1005-1008. doi:10.1210/endo.140.2.6673PubMedGoogle ScholarCrossref
29.
Nakamichi  Y, Udagawa  N, Suda  T, Takahashi  N.  Mechanisms involved in bone resorption regulated by vitamin D.  J Steroid Biochem Mol Biol. 2018;177:70-76. doi:10.1016/j.jsbmb.2017.11.005PubMedGoogle ScholarCrossref
30.
Jorde  R, Sneve  M, Torjesen  PA, Figenschau  Y, Hansen  J-B, Grimnes  G.  No significant effect on bone mineral density by high doses of vitamin D 3 given to overweight subjects for one year.  Nutr J. 2010;7(9):1. doi:10.1186/1475-2891-9-1.PubMedGoogle ScholarCrossref
31.
Hansen  KE, Johnson  RE, Chambers  KR,  et al.  Treatment of vitamin D insufficiency in postmenopausal women.  JAMA Intern Med. 2015;175(10):1612-1621. doi:10.1001/jamainternmed.2015.3874PubMedGoogle ScholarCrossref
32.
Pop  LC, Sukumar  D, Schneider  SH,  et al.  Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial.  Osteoporos Int. 2017;28(1):377-388. doi:10.1007/s00198-016-3735-zPubMedGoogle ScholarCrossref
33.
Smith  LM, Gallagher  JC, Kaufmann  M, Jones  G.  Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women.  J Intern Med. 2018;284(6):685-693. doi:10.1111/joim.12825PubMedGoogle ScholarCrossref
34.
Sanders  KM, Nicholson  GC, Ebeling  PR.  Is high dose vitamin D harmful?  Calcif Tissue Int. 2013;92(2):191-206. doi:10.1007/s00223-012-9679-1PubMedGoogle ScholarCrossref
35.
Sanders  KM, Stuart  AL, Williamson  EJ,  et al.  Annual high-dose oral vitamin D and falls and fractures in older women.  JAMA. 2010;303(18):1815-1822. doi:10.1001/jama.2010.594PubMedGoogle ScholarCrossref
36.
Khaw  K-T, Stewart  AW, Waayer  D,  et al.  Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial.  Lancet Diabetes Endocrinol. 2017;5(6):438-447. doi:10.1016/S2213-8587(17)30103-1PubMedGoogle ScholarCrossref
37.
Malihi  Z, Wu  Z, Stewart  AW, Lawes  CMM, Scragg  R.  Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation.  Am J Clin Nutr. 2016;104(4):1039-1051. doi:10.3945/ajcn.116.134981PubMedGoogle ScholarCrossref
38.
Aloia  JF, Katumuluwa  S, Stolberg  A,  et al.  Safety of calcium and vitamin D supplements, a randomized controlled trial.  Clin Endocrinol (Oxf). 2018;89(6):742-749. doi:10.1111/cen.13848PubMedGoogle ScholarCrossref
39.
Manson  JE, Cook  NR, Lee  I-M,  et al; VITAL Research Group.  Vitamin D supplements and prevention of cancer and cardiovascular disease.  N Engl J Med. 2019;380(1):33-44. doi:10.1056/NEJMoa1809944PubMedGoogle ScholarCrossref
Original Investigation
August 27, 2019

Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial

Author Affiliations
  • 1McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary, Calgary, Canada
  • 2Research Facilitation, Alberta Health Services, Calgary, Canada
JAMA. 2019;322(8):736-745. doi:10.1001/jama.2019.11889
Key Points

Question  Does higher-dose vitamin D supplementation improve bone mineral density (BMD, measured using high-resolution peripheral quantitative computed tomography) and bone strength (measured as failure load)?

Findings  In this randomized clinical trial that included 311 healthy adults, treatment with vitamin D for 3 years at a dose of 4000 IU per day or 10 000 IU per day, compared with 400 IU per day, resulted in statistically significant lower radial BMD (calcium hydroxyapatite; −3.9 mg HA/cm3 and −7.5 mg HA/cm3, respectively); tibial BMD was significantly lower only with the daily dose of 10 000 IU. There were no significant differences in bone strength at either the radius or tibia.

Meaning  Among healthy adults, supplementation with higher doses of vitamin D did not result in improved bone health; further research would be needed to determine whether it is harmful.

Abstract

Importance  Few studies have assessed the effects of daily vitamin D doses at or above the tolerable upper intake level for 12 months or greater, yet 3% of US adults report vitamin D intakes of at least 4000 IU per day.

Objective  To assess the dose-dependent effect of vitamin D supplementation on volumetric bone mineral density (BMD) and strength.

Design, Setting, and Participants  Three-year, double-blind, randomized clinical trial conducted in a single center in Calgary, Canada, from August 2013 to December 2017, including 311 community-dwelling healthy adults without osteoporosis, aged 55 to 70 years, with baseline levels of 25-hydroxyvitamin D (25[OH]D) of 30 to 125 nmol/L.

Interventions  Daily doses of vitamin D3 for 3 years at 400 IU (n = 109), 4000 IU (n = 100), or 10 000 IU (n = 102). Calcium supplementation was provided to participants with dietary intake of less than 1200 mg per day.

Main Outcomes and Measures  Co-primary outcomes were total volumetric BMD at radius and tibia, assessed with high resolution peripheral quantitative computed tomography, and bone strength (failure load) at radius and tibia estimated by finite element analysis.

Results  Of 311 participants who were randomized (53% men; mean [SD] age, 62.2 [4.2] years), 287 (92%) completed the study. Baseline, 3-month, and 3-year levels of 25(OH)D were 76.3, 76.7, and 77.4 nmol/L for the 400-IU group; 81.3, 115.3, and 132.2 for the 4000-IU group; and 78.4, 188.0, and 144.4 for the 10 000-IU group. There were significant group × time interactions for volumetric BMD. At trial end, radial volumetric BMD was lower for the 4000 IU group (−3.9 mg HA/cm3 [95% CI, −6.5 to −1.3]) and 10 000 IU group (−7.5 mg HA/cm3 [95% CI, −10.1 to −5.0]) compared with the 400 IU group with mean percent change in volumetric BMD of −1.2% (400 IU group), −2.4% (4000 IU group), and −3.5% (10 000 IU group). Tibial volumetric BMD differences from the 400 IU group were −1.8 mg HA/cm3 (95% CI, −3.7 to 0.1) in the 4000 IU group and −4.1 mg HA/cm3 in the 10 000 IU group (95% CI, −6.0 to −2.2), with mean percent change values of −0.4% (400 IU), −1.0% (4000 IU), and −1.7% (10 000 IU). There were no significant differences for changes in failure load (radius, P = .06; tibia, P = .12).

Conclusions and Relevance  Among healthy adults, treatment with vitamin D for 3 years at a dose of 4000 IU per day or 10 000 IU per day, compared with 400 IU per day, resulted in statistically significant lower radial BMD; tibial BMD was significantly lower only with the 10 000 IU per day dose. There were no significant differences in bone strength at either the radius or tibia. These findings do not support a benefit of high-dose vitamin D supplementation for bone health; further research would be needed to determine whether it is harmful.

Trial Registration  ClinicalTrials.gov Identifier: NCT01900860

×